Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -123018.64% is 4260% below its 5-year average of -2821.46%, near the low end of its 5-year range (-123018.64%–27.62%).
510.04% below its 12-month average of -20165.65%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2025 (2025-12-31): -33433.90%.
EBITDA MARGIN
-123018.64%
EBITDA MARGIN AVG TTM
-20165.65%
EBITDA MARGIN AVG 3Y
-6454.71%
EBITDA MARGIN AVG 5Y
-2821.46%
EBITDA MARGIN AVG 10Y
-722.93%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-510.04%
CURRENT VS 3Y AVG
-1805.87%
CURRENT VS 5Y AVG
-4260.10%
CURRENT VS 10Y AVG
-16916.76%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Avalo Therapeutics, Inc.
Market Cap
$767.46M
EBITDA Margin
-123018.64%
TTM Avg
-20165.65%
3Y Avg
-6454.71%
5Y Avg
-2821.46%
Market Cap
$774.32M
EBITDA Margin
-4915.19%
TTM Avg
-4915.19%
3Y Avg
-4915.19%
5Y Avg
-4915.19%
Market Cap
$775.72M
EBITDA Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$776.24M
EBITDA Margin
-28.62%
TTM Avg
-126.34%
3Y Avg
-26187.68%
5Y Avg
-23869.36%
Market Cap
$780.95M
EBITDA Margin
18.47%
TTM Avg
18.88%
3Y Avg
13.21%
5Y Avg
14.52%
Market Cap
$749.55M
EBITDA Margin
-27116.80%
TTM Avg
-23848.80%
3Y Avg
-16467.00%
5Y Avg
-16467.00%
Market Cap
$786.48M
EBITDA Margin
-14.10%
TTM Avg
-9.55%
3Y Avg
-6.60%
5Y Avg
-0.48%
Market Cap
$734.10M
EBITDA Margin
-4821.38%
TTM Avg
-3832.53%
3Y Avg
-2582.73%
5Y Avg
-1806.92%
Market Cap
$719.64M
EBITDA Margin
-414.93%
TTM Avg
-258.43%
3Y Avg
-185.54%
5Y Avg
-212.52%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | $767.46M | -123018.64% | -20165.65% | -6454.71% | -2821.46% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $774.32M | -4915.19% | -4915.19% | -4915.19% | -4915.19% |
| Design Therapeutics, Inc. (DSGN)vs › | $775.72M | 0.00% | 0.00% | 0.00% | 0.00% |
| Geron Corporation (GERN)vs › | $776.24M | -28.62% | -126.34% | -26187.68% | -23869.36% |
| AdaptHealth Corp. (AHCO)vs › | $780.95M | 18.47% | 18.88% | 13.21% | 14.52% |
| Candel Therapeutics, Inc. (CADL)vs › | $749.55M | -27116.80% | -23848.80% | -16467.00% | -16467.00% |
| Cytek Biosciences, Inc. (CTKB)vs › | $786.48M | -14.10% | -9.55% | -6.60% | -0.48% |
| Anteris Technologies Global Corp. (AVR)vs › | $734.10M | -4821.38% | -3832.53% | -2582.73% | -1806.92% |
| Achieve Life Sciences, Inc. (ACHV)vs › | $719.64M | -414.93% | -258.43% | -185.54% | -212.52% |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.33M | 52.93% | 53.31% | 49.89% | 44.80% |
Gross Margin
100.0%
EBITDA Margin
-123018.6%
Operating Margin
-123601.7%
Net Margin
-170055.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-31 | -33433.90% |
| 2024-12-31 | -6897.40% |
| 2024-09-30 | -5151.41% |
| 2023-12-31 | -649.39% |
| 2023-09-30 | -1571.61% |
| 2023-06-30 | -1105.60% |
| 2023-03-31 | -1844.00% |
| 2022-12-31 | -984.38% |
| 2022-09-30 | 27.62% |
| 2022-06-30 | -1142.11% |
| 2022-03-31 | -1772.04% |
| 2021-12-31 | -8067.58% |
| 2021-09-30 | -1185.78% |
| 2021-06-30 | -778.54% |
| 2021-03-31 | -6369.77% |
| 2020-12-31 | -4829.99% |
| 2020-09-30 | -1156.66% |
| 2020-06-30 | -851.19% |
| 2020-03-31 | -1124.17% |
| 2019-12-31 | -13.68% |
| 2019-09-30 | -47.25% |
| 2019-06-30 | -109.47% |
| 2019-03-31 | -109.48% |
| 2018-12-31 | -92.95% |
| 2018-09-30 | -568.32% |
| 2018-06-30 | -94.04% |
| 2018-03-31 | -55.07% |
| 2017-12-31 | -176.79% |
| 2017-09-30 | 87.57% |
| 2017-06-30 | -1121.13% |
| 2017-03-31 | -492.78% |
| 2016-12-31 | -922.86% |
| 2016-09-30 | -1852.66% |
| 2016-06-30 | -535.20% |
| 2013-12-31 | -20.92% |
